Combination Treatment With VELCADE and Low-Dose Tissue Plasminogen Activator Provides Potent Neuroprotection in Aged Rats After Embolic Focal Ischemia

BACKGROUND AND PURPOSE: Treatment with a selective proteasome inhibitor, VELCADE, in combination with tissue plasminogen activator (tPA) extended the therapeutic window to 6 hours in young rats after stroke. However, stroke is a major cause of death and disability in the elderly. The present study i...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Zhang, Li, Zhang, Zheng Gang, Buller, Ben, Jiang, James, Jiang, Yanting, Zhao, Danping, Liu, Xianshuang, Morris, Dan, Chopp, Michael
פורמט: Artigo
שפה:Inglês
יצא לאור: 2010
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2860668/
https://ncbi.nlm.nih.gov/pubmed/20203318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.109.577288
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים